Developmental Research Program

发展研究计划

• 批准号: 10708758
• 负责人: Jason S. Lewis
• 金额: $ 11.08万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708758
• 关键词: Award; Clinical Trials; Collaborations; Combined Modality Therapy; Data; Development; Doctor of Philosophy; Eligibility Determination; Extramural Activities; Faculty; Funding; Genomics; Goals; Immunotherapeutic agent; Individual; Institution; Investigation; Islet Cell Tumor; Leadership; Malignant neoplasm of pancreas; Memorial Sloan-Kettering Cancer Center; Outcome; Pancreas; Participant; Patient Care; Peer Review; Pilot Projects; Program Research Project Grants; Publications; Qualifying; Recording of previous events; Request for Proposals; Research; Research Personnel; Research Support; Resources; Translational Research; Underrepresented Populations; United States National Institutes of Health; Universities; Vision; Women' s Group; anticancer research; base; biomarker development; clinical care; diversity and inclusion; innovation; medical schools; novel strategies; pancreatic neoplasm; preference; programs; radiomics; stem; success; translational cancer research; translational goal

PROJECT SUMMARY/ABSTRACT – DRP The goals of the Developmental Research Program (DRP) of the MSK Pancreas SPORE are to expand the breadth of the translational pancreatic cancer research base and to encourage highly innovative investigations that have major potential to impact pancreatic cancer outcomes. DRP funds, supplemented by institutional funds, will allow us to support 2 exceptional pilot projects each year. We will request proposals for pilot projects with a clear translational focus and with potential to ultimately impact clinical care of patients with pancreatic neoplasms. Investigators (MD, MD/PhD, DO, or PhD) with a demonstrated history of pancreas cancer research appointed at MSK or a neighboring institution, Weill Cornell Medical College and the Rockefeller University, will be eligible to apply. Applications will be peer-reviewed by the CEP/DRP Selection Committee, which is composed of the SPORE PIs, DRP and CEP Leaders, select MSK Departmental and Divisional Chairs, and representatives from the MSK Equality, Diversity & Inclusion Council. The most meritorious projects based on defined review criteria will be selected. Preference will be given to projects that advance the long-term research goals of the SPORE and have high potential to become full SPORE projects. We will prioritize projects submitted by early-stage investigators and are committed to promoting diversity and strengthening the participation of women and underrepresented groups in translational research. DRP awardees will have full access to SPORE Core resources, will benefit from the expertise of the SPORE investigative team, and will be active participants in the SPORE. The scientific progress of DRP projects will be evaluated every six months by the DRP Leaders. Long-term metrics of success for DRP awardees include presentation/publication of original research, successful competition for independent research support, successful development and completion of clinical trials stemming from DRP research, establishment of new collaborations, and institutional recognition by academic promotion. DRP projects that make significant progress towards their translational goals will be eligible for a second year of funding and have the potential to be promoted to full SPORE projects.

项目总结/摘要- DRP MSK胰腺孢子的发展研究计划（DRP）的目标是扩大 广泛的转化胰腺癌研究基础，并鼓励高度创新的研究 对胰腺癌的预后有很大的影响。减少灾害风险方案资金，加上机构资金， 我们每年将支持两个特殊的试点项目。我们将征求试点项目的建议书， 明确的翻译重点，并有可能最终影响胰腺癌患者的临床护理 肿瘤。具有胰腺癌研究史的研究者（MD、MD/PhD、DO或PhD） 任命在MSK或邻近机构，威尔康奈尔医学院和洛克菲勒大学，将 有资格申请。申请将由CEP/DRP遴选委员会进行同行评审， 由SPORE PI、DRP和CEP领导人组成，选择MSK部门和部门主席，以及 MSK平等、多样性和包容理事会的代表。最有价值的项目基于 将选定确定的审查标准。将优先考虑促进长期研究的项目 目标，并有很大的潜力成为完整的SPORE项目。我们将优先考虑提交的项目 并致力于促进多样性和加强参与 妇女和翻译研究中代表性不足的群体。DRP获奖者将完全访问SPORE 核心资源，将受益于SPORE调查团队的专业知识，并将积极参与 在孢子。DRP领导人将每六个月对DRP项目的科学进展进行一次评估。 DRP获奖者的长期成功指标包括原创研究的展示/出版，成功的 独立研究支持的竞争，成功开发和完成临床试验， 从DRP研究，建立新的合作，并通过学术机构的认可， 推广.在实现其转化目标方面取得重大进展的DRP项目将有资格获得 第二年的资金，并有可能被推广到完整的SPORE项目。